{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:13:45Z","timestamp":1792289625906,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.beem.2008.09.003","type":"journal-article","created":{"date-parts":[[2009,3,12]],"date-time":"2009-03-12T04:23:52Z","timestamp":1236831832000},"page":"133-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":233,"title":["Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression"],"prefix":"10.1016","volume":"23","author":[{"given":"Fabr\u00edcio A.","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2008.09.003_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0091-3057(91)90347-5","article-title":"A random walk through a cannabis field","volume":"40","author":"Mechoulam","year":"1991","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.beem.2008.09.003_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","article-title":"History of cannabis as a medicine: a review","volume":"28","author":"Zuardi","year":"2006","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"10.1016\/j.beem.2008.09.003_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nature reviews. Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.beem.2008.09.003_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"168","author":"Mackie","year":"2005","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib6","first-page":"1","article-title":"Endocannabinoids: synthesis and degradation","volume":"160","author":"Di Marzo","year":"2008","journal-title":"Reviews of Physiology Biochemistry and Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib7","first-page":"27","article-title":"Neuromodulatory functions of the endocannabinoid system","volume":"29","author":"Marsicano","year":"2006","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2008.09.003_bib8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0140-6736(98)05021-1","article-title":"Adverse effects of cannabis","volume":"352","author":"Hall","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2008.09.003_bib9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/1073858406296601","article-title":"Functional imaging studies in cannabis users","volume":"13","author":"Chang","year":"2007","journal-title":"Neuroscientist"},{"key":"10.1016\/j.beem.2008.09.003_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0006-8993(98)00549-6","article-title":"A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrain","volume":"802","author":"McGregor","year":"1998","journal-title":"Brain Research"},{"key":"10.1016\/j.beem.2008.09.003_bib11","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1523\/JNEUROSCI.1636-07.2007","article-title":"Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex","volume":"27","author":"Bambico","year":"2007","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.neuropharm.2006.10.013","article-title":"Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray","volume":"52","author":"Moreira","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuropharm.2007.06.024","article-title":"CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour","volume":"54","author":"Rubino","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/cercor\/bhm161","article-title":"Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex","volume":"18","author":"Rubino","year":"2008","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.beem.2008.09.003_bib15","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.beem.2008.09.003_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature00839","article-title":"The endogenous cannabinoid system controls extinction of aversive memories","volume":"418","author":"Marsicano","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.beem.2008.09.003_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1124\/jpet.106.101287","article-title":"Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling","volume":"318","author":"Patel","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.beem.2008.09.003_bib19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.tpj.6500466","article-title":"Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice","volume":"8","author":"Steiner","year":"2008","journal-title":"The Pharmacogenomics Journal"},{"key":"10.1016\/j.beem.2008.09.003_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1369-1600.2008.00104.x","article-title":"The endocannabinoid system: emotion, learning and addiction","volume":"13","author":"Moreira","year":"2008","journal-title":"Addiction Biology"},{"key":"10.1016\/j.beem.2008.09.003_bib21","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","article-title":"Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain","volume":"11","author":"Marsicano","year":"1999","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib22","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1523\/JNEUROSCI.19-11-04544.1999","article-title":"Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons","volume":"19","author":"Katona","year":"1999","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.neuron.2006.07.006","article-title":"The endocannabinoid system controls key epileptogenic circuits in the hippocampus","volume":"51","author":"Monory","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.beem.2008.09.003_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.brainres.2006.09.110","article-title":"Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex","volume":"1127","author":"Oropeza","year":"2007","journal-title":"Brain Research"},{"key":"10.1016\/j.beem.2008.09.003_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuroscience.2005.06.043","article-title":"Redistribution of CB1 cannabinoid receptors during evolution of cholinergic basal forebrain territories and their cortical projection areas: a comparison between the gray mouse lemur (Microcebus murinus, primates) and rat","volume":"135","author":"Harkany","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib26","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.neuroscience.2007.02.021","article-title":"Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice","volume":"146","author":"H\u00e4ring","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib27","doi-asserted-by":"crossref","first-page":"E693","DOI":"10.1208\/aapsj080479","article-title":"Endocannabinoid mechanisms of pain modulation","volume":"8","author":"Hohmann","year":"2006","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.beem.2008.09.003_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.bjp.0707433","article-title":"Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain","volume":"152","author":"Jhaveri","year":"2007","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib29","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nn1916","article-title":"Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors","volume":"10","author":"Agarwal","year":"2007","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.physbeh.2005.08.045","article-title":"Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting","volume":"87","author":"Parker","year":"2006","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.beem.2008.09.003_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00213-007-0970-1","article-title":"The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat","volume":"196","author":"Rock","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.beem.2008.09.003_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.beem.2008.09.003_bib33","first-page":"108","article-title":"Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids","volume":"79","author":"Martin","year":"1987","journal-title":"NIDA Research Monograph"},{"key":"10.1016\/j.beem.2008.09.003_bib34","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1371\/journal.pbio.0050269","article-title":"Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice","volume":"5","author":"Monory","year":"2007","journal-title":"PLoS Biology"},{"key":"10.1016\/j.beem.2008.09.003_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00213-002-1144-9","article-title":"Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol","volume":"163","author":"Berrendero","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.beem.2008.09.003_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euroneuro.2005.03.003","article-title":"Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test","volume":"15","author":"Hill","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib37","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1172\/JCI25509","article-title":"Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects","volume":"115","author":"Jiang","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.beem.2008.09.003_bib38","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0022-3565(25)13195-9","article-title":"Pharmacological characterization of cannabinoids in the elevated plus maze","volume":"253","author":"Onaivi","year":"1990","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.beem.2008.09.003_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s002130050013","article-title":"A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice","volume":"147","author":"Valjent","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.beem.2008.09.003_bib40","doi-asserted-by":"crossref","unstructured":"Micale V, Cristino L, Tamburella A, et\u00a0al. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 25 June 2008. doi:10.1038\/npp.2008.98.","DOI":"10.1038\/npp.2008.98"},{"key":"10.1016\/j.beem.2008.09.003_bib41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1046\/j.1460-9568.2002.02192.x","article-title":"The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety","volume":"16","author":"Haller","year":"2002","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","article-title":"Involvement of CB1 cannabinoid receptors in emotional behaviour","volume":"159","author":"Martin","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.beem.2008.09.003_bib43","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1523\/JNEUROSCI.3303-06.2007","article-title":"Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice","volume":"27","author":"Marsch","year":"2007","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2007.07.005","article-title":"Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors","volume":"54","author":"Moreira","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2003","journal-title":"Natural Medicines"},{"key":"10.1016\/j.beem.2008.09.003_bib46","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.beem.2008.09.003_bib47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","article-title":"Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress","volume":"62","author":"Bortolato","year":"2007","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.beem.2008.09.003_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejphar.2004.06.069","article-title":"Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress","volume":"499","author":"Hill","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2007.11.017","article-title":"Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol","volume":"94","author":"Vann","year":"2008","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.beem.2008.09.003_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib51","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/cbdv.200790147","article-title":"Cannabidiol\u2013recent advances","volume":"4","author":"Mechoulam","year":"2007","journal-title":"Chemistry & Biodiversity"},{"key":"10.1016\/j.beem.2008.09.003_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.toxicon.2004.05.009","article-title":"The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans","volume":"44","author":"Carlini","year":"2004","journal-title":"Toxicon"},{"key":"10.1016\/j.beem.2008.09.003_bib53","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nrn2253","article-title":"cannabis, the mind and society: the hash realities","volume":"8","author":"Murray","year":"2007","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib54","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2146\/ajhp060471","article-title":"Medical marijuana and the developing role of the pharmacist","volume":"64","author":"Seamon","year":"2007","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.beem.2008.09.003_bib55","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.pnpbp.2004.05.027","article-title":"Adverse effects of cannabis on health: an update of the literature since 1996","volume":"28","author":"Kalant","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.beem.2008.09.003_bib56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1526-4637.2006.00085.x","article-title":"Experience with the synthetic cannabinoid nabilone in chronic noncancer pain","volume":"7","author":"Berlach","year":"2006","journal-title":"Pain Medicine"},{"key":"10.1016\/j.beem.2008.09.003_bib57","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(95)90485-9","article-title":"Nabilone in the treatment of multiple sclerosis","volume":"345","author":"Martyn","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2008.09.003_bib58","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","article-title":"Nabilone for the treatment of pain in fibromyalgia","volume":"9","author":"Skrabek","year":"2008","journal-title":"The Journal of Pain"},{"key":"10.1016\/j.beem.2008.09.003_bib59","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1523\/JNEUROSCI.5603-07.2008","article-title":"Cannabinoid modulation of amygdala reactivity to social signals of threat in humans","volume":"28","author":"Phan","year":"2008","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-002-1231-y","article-title":"Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans","volume":"164","author":"Hart","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.beem.2008.09.003_bib61","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chemistry & Biodiversity"},{"key":"10.1016\/j.beem.2008.09.003_bib62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug","volume":"39","author":"Zuardi","year":"2006","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1016\/j.beem.2008.09.003_bib63","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2008.09.003_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.pain.2004.09.013","article-title":"Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial","volume":"112","author":"Berman","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.beem.2008.09.003_bib65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pain.2007.08.028","article-title":"Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial","volume":"133","author":"Nurmikko","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.beem.2008.09.003_bib66","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.beem.2008.09.003_bib67","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/1352458505070618","article-title":"Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis","volume":"12","author":"Wade","year":"2006","journal-title":"Multiple sclerosis"},{"key":"10.1016\/j.beem.2008.09.003_bib68","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1360-0443.1999.94913114.x","article-title":"Marijuana withdrawal among adults seeking treatment for marijuana dependence","volume":"94","author":"Budney","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.beem.2008.09.003_bib69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/10550490802019519","article-title":"Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions?","volume":"17","author":"Agrawal","year":"2008","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.beem.2008.09.003_bib70","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1360-0443.2008.02158.x","article-title":"Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents","volume":"103","author":"Chung","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.beem.2008.09.003_bib71","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","article-title":"The endocannabinoid system in obesity and type 2 diabetes","volume":"51","author":"Marzo","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2008.09.003_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1369-1600.2008.00113.x","article-title":"Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies","volume":"13","author":"Le Foll","year":"2008","journal-title":"Addiction Biology"},{"key":"10.1016\/j.beem.2008.09.003_bib73","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.beem.2008.09.003_bib74","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00001756-199701200-00023","article-title":"Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat","volume":"8","author":"Navarro","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.beem.2008.09.003_bib75","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008877-200509000-00013","article-title":"Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice","volume":"16","author":"Rodgers","year":"2005","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib76","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1523\/JNEUROSCI.0153-06.2006","article-title":"Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes","volume":"26","author":"Kamprath","year":"2006","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib77","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1111\/j.1460-9568.2008.06266.x","article-title":"Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation","volume":"27","author":"Patel","year":"2008","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib78","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1210\/en.2005-1649","article-title":"Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function","volume":"148","author":"Cota","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2008.09.003_bib79","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1210\/en.2004-0638","article-title":"Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis","volume":"145","author":"Patel","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2008.09.003_bib80","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1460-9568.2005.03916.x","article-title":"Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling","volume":"21","author":"Patel","year":"2005","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.beem.2008.09.003_bib81","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1096\/fj.05-3995fje","article-title":"The endocannabinoid system drives neural progenitor proliferation","volume":"19","author":"Aguado","year":"2005","journal-title":"FASEB Journal"},{"key":"10.1016\/j.beem.2008.09.003_bib82","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1471-4159.2007.05149.x","article-title":"BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice","volume":"105","author":"Aso","year":"2008","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.beem.2008.09.003_bib83","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00008877-200509000-00006","article-title":"Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?","volume":"16","author":"Hill","year":"2005","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2007.09.008","article-title":"Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice","volume":"33","author":"Steiner","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.beem.2008.09.003_bib85","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008877-200312000-00001","article-title":"Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice","volume":"14","author":"Shearman","year":"2003","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib86","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biopsych.2004.10.032","article-title":"Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents","volume":"57","author":"Griebel","year":"2005","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.beem.2008.09.003_bib87","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.bjp.0705100","article-title":"The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions","volume":"138","author":"Tzavara","year":"2003","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib88","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.tips.2005.10.006","article-title":"A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders","volume":"26","author":"Witkin","year":"2005","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.beem.2008.09.003_bib89","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.beem.2008.09.003_bib90","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2008.09.003_bib91","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2008.09.003_bib92","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2008.09.003_bib93","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2008.09.003_bib94","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.2337\/dc08-s258","article-title":"Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program","volume":"31","author":"Van Gaal","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2008.09.003_bib95","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2008.09.003_bib96","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2008.09.003_bib97","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0091270008314467","volume":"48","author":"Addy","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib98","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0091270008317591","article-title":"Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers","volume":"48","author":"Addy","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.beem.2008.09.003_bib99","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","article-title":"The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake","volume":"7","author":"Addy","year":"2008","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.beem.2008.09.003_bib100","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/archinte.163.17.2058","article-title":"Depression in association with severe obesity: changes with weight loss","volume":"163","author":"Dixon","year":"2003","journal-title":"Archives of Internal Medicine"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X08001012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X08001012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:40:39Z","timestamp":1761496839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X08001012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1521690X08001012"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2008.09.003","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2008.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}